All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Chief of Cancer Survivorship Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

December 11th 2023

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has appointed Louise Ligresti, MD, as chief of Cancer Survivorship at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

December 11th 2023

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

December 11th 2023

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

December 11th 2023

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

December 11th 2023

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

December 11th 2023

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Final APPLY-PNH Data Support Use of Iptacopan in PNH With Persistent Anemia

December 11th 2023

Oral iptacopan (Fabhalta) monotherapy induced durable responses and hemolysis control in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia who had previously received anti-C5 treatment.

Brentuximab Vedotin Combo Elicits Responses in Advanced Classical Hodgkin Lymphoma

December 11th 2023

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

December 11th 2023

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

December 11th 2023

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

December 11th 2023

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

AI May Spare Breast Cancer Patients Unnecessary Treatments

December 11th 2023

A new artificial intelligence tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes.

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

December 10th 2023

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

December 10th 2023

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL

December 10th 2023

Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.

Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR

December 10th 2023

Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment.

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

December 10th 2023

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

December 10th 2023

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML

December 10th 2023

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.